Equity
€924,327 ▲ 35.4%
CADRATHA has made a profit in every financial year since 2011.
CADRATHA
Lifetime
15 annual accounts with figures on one time axispeak of €521,992 in 2025
€521,992▲ 96.9%
peak of €345,192 in 2025
€345,192▲ 84.9%
peak of €924,327 in 2025
€924,327▲ 35.4%
€206,814▲ 72.9%
Board1 name since 2010
1 director
Documentsfilings and deeds
17-06-202644 days before the deadline
2025micro format
Gross margin from €265,083 to €521,992Result from €186,704 to €345,192Dividend €103,628Equity from €682,763 to €924,327Debts from €119,642 to €206,814Investments €136,838
Key points
from the 2025 annual accountsResult
€345,192 ▲ 84.9%
The result rose in 2025 from €186,704 to €345,192.
Debts
€206,814 ▲ 72.9%
Debts rose by €87,172 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.
Investments
€154,504 5.5 times depreciation
Green is investment, beige is depreciation. Land and buildings stand 20.9% higher than in 2024.
Filings
15 annual accounts since 2011
Two of the last ten came late. The 2018 accounts came in latest, 20 days after the end of the period.
Position in the sector
€345,192
Higher net result than 95% of companies in human health. Sector median €59,543 · 21,321 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 17,811 companies had the same profile as CADRATHA has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,811 companies, not a prediction for CADRATHA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0826772570
Change of role: , from manager to director
Director discharge: · General meeting of 30-03-2023 · Gazette deed
Registered office moved from Montigny-le-Tilleul to Gerpinnes
The registered office moved from rue du Faubourg Saint Lazare 63 à 6110 Montigny-Le-Tilleul to allée des Bouleaux 64 6280 Gerpinnes · Gazette deed
Incorporation
published on 30-06-2010 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| CADRATHA Gerpinnes | €1.1m | €521,992 | 81.7% | - |
| PILET & PILET RADIOLOGIE Kortrijk | €1.1m | €578,329 | 66.9% | - |
| BIOPAR Silly | €1.4m | €398,758 | 96.9% | - |
| CENTRE D'IMAGERIE MEDICALE ET DE RADIOLOGIE Mons | €0.8m | €487,544 | 72.6% | - |
| CENTRE DE RADIOLOGIE DU FORT Chaudfontaine | €1.1m | €465,082 | 69.0% | 1.9 |
| DOKTER JACOBS NADIA Ranst | €1.1m | €554,930 | 91.5% | - |
| DR GEENS JEROEN Buggenhout | €1.4m | €457,268 | 56.4% | - |
These companies have the same main activity as CADRATHA: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €832,000 and €1.4m, founded between 2006 and 2011.
Official details
Source: KBO- Status
- Active since 18-06-2010Normal situation
- Activity
- Medical imaging and medical laboratoriesNACE 86910
- Establishment unit
- 2.189.956.7266110 Montigny-le-Tilleul, since 18-06-2010
- Financial year end
- 31 December
- Peppol
- Reachable since 12-12-2025
Annual accounts 2025
- ≈ €770,000estimated
- €1.1m▲ 41.0%
- Filing
- Filed on 17-06-2026, 44 days before the end of the filing period
Insights on CADRATHA
CADRATHA files the micro format. That format states no turnover. The gross margin rose from €374,893 in 2011 to €521,992 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CADRATHA
- What is the company number of CADRATHA?
- The company number of CADRATHA is 0826.772.570. The VAT number is the same number with BE in front: BE 0826.772.570.
- Where is CADRATHA based?
- The registered office is at Allée des Bouleaux 64, 6280 Gerpinnes.Company details
- What does CADRATHA do?
- According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
- What is the legal form of CADRATHA?
- CADRATHA is a private limited company (BV).
- When was CADRATHA founded?
- CADRATHA was founded on 18-06-2010.
- Is CADRATHA still active?
- Yes, CADRATHA is an active enterprise in the KBO register.
- What is the turnover of CADRATHA?
- The turnover in financial year 2025 is ≈ €770,000. This figure is estimated from the gross margin of €521,992 and 48 comparable companies (NACE 86). It probably lies between €640,000 and €970,000.Financials
- Is CADRATHA profitable?
- In financial year 2025, CADRATHA made a profit of €345,192.
- Where can I find the annual accounts of CADRATHA?
- CADRATHA filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CADRATHA due?
- CADRATHA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.